Literature DB >> 4033929

Central nervous system toxicity with high-dose Ara-C.

T L Hwang, W K Yung, E H Estey, W S Fields.   

Abstract

We evaluated the CNS complications in 118 adults with acute leukemia who received IV high-dose Ara-C therapy. Fourteen (12%) had cerebellar signs, encephalopathy, seizures, or leukoencephalopathy. Symptoms usually occurred within 24 hours after the last treatment. Patients receiving a cumulative dose in excess of 24 g/m2 had more severe or irreversible symptoms. After lower cumulative doses, symptoms often resolved even though treatment was continued. The incidence of CNS complications of high-dose Ara-C is acceptable and is potentially reversible if appropriate precautions are taken.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033929     DOI: 10.1212/wnl.35.10.1475

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Drug treatment of acute leukaemia. Current status.

Authors:  S M Donohue; C P Charlton
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

2.  Bell's palsy and HIV infection.

Authors:  M M Brown; A Thompson; B T Goh; G E Forster; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

Review 3.  Atypical MRI findings in treatment-related leukoencephalopathy: case report.

Authors:  Y Ohmoto; K Kajiwara; S Kato; T Nisizaki; H Ito; S Tamura
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

4.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 5.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

6.  Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Akihiro Iguchi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2014-09-13       Impact factor: 2.490

7.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

8.  Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate.

Authors:  W Boogerd; J J vd Sande; D Moffie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

9.  Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.

Authors:  M Gore; R Powles; A Lakhani; S Milan; J Maitland; G Goss; A Nandi; T Perren; G Forgeson; J Treleaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 10.  Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.

Authors:  Nicholas S Phillips; Elizabeth S Duke; Hannah-Lise T Schofield; Nicole J Ullrich
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.